Does Covered California Cover Zepbound? Carriers, Costs, Denials

Whether Covered California covers Zepbound depends entirely on which carrier you enrolled with and whether you meet that insurer’s clinical criteria. No Covered California plan covers Zepbound automatically. Every carrier that offers any coverage requires prior authorization, most set a body mass index threshold well above the FDA’s label, and most demand documented participation in a structured weight-management program. A few carriers exclude weight-loss drugs almost entirely. Patients prescribed Zepbound for obstructive sleep apnea have a separate and often easier path to approval.

Zepbound (tirzepatide) is FDA-approved for chronic weight management in adults with a BMI of 30 or greater, or 27 or greater with a weight-related condition such as hypertension, type 2 diabetes, or obstructive sleep apnea.¹ In December 2024 the FDA also approved it as the first medication for moderate-to-severe obstructive sleep apnea in adults with obesity.² Those two indications matter because they open different coverage doors with your insurer.

There is no federal ACA requirement that marketplace plans cover anti-obesity medications, and California’s Essential Health Benefits benchmark plan does not include them.³ Each Covered California carrier builds its own formulary and sets its own rules.⁴ That is why the answer varies so much from one plan card to another.

Coverage By Carrier

Blue Shield of California

As of January 1, 2025, Zepbound is no longer automatically covered for Blue Shield’s commercial HMO and PPO members, including Covered California enrollees. Coverage now requires prior authorization and a determination of medical necessity for Class III (morbid) obesity, meaning a BMI of 40 or higher. Members must also be participating in a comprehensive weight-loss program that includes a reduced-calorie diet, physical activity, and behavioral therapy. Members who do not meet these requirements pay the full cost.⁵

Health Net

Health Net covers Zepbound on its individual and family plans (including Ambetter HMO and PPO plans sold through Covered California) with prior authorization.⁶ Marketplace enrollees generally must have a BMI of 40 or higher and must have been enrolled in an approved weight-loss program for at least six months before starting the medication.⁷ The standard cost share is 50% coinsurance. Members already receiving a GLP-1 for a BMI of 30 or higher may be grandfathered if their provider continues the prescription.⁸

Anthem Blue Cross

Anthem reclassified all GLP-1 medications as non-formulary Tier 4 specialty drugs effective January 1, 2025. They require prior authorization and are typically denied as an exclusion for weight-loss purposes. Authorization is now required even for non-obesity indications.⁹

Kaiser Permanente

Kaiser does not list Zepbound on its standard commercial HMO formulary.¹⁰ Kaiser’s general policy does allow non-formulary drugs to be covered when a Kaiser physician determines the drug is medically appropriate and necessary, with out-of-pocket costs depending on the plan.⁹

UnitedHealthcare

UnitedHealthcare’s California fully insured plans cover Zepbound with prior authorization. Members must have a BMI of 30 or higher, or 27 with an obesity-related comorbidity, and must participate in a motivation-based wellness program. The medication generally falls under Tier 3.⁹ UnitedHealthcare also maintains a separate coverage pathway when Zepbound is prescribed for obstructive sleep apnea.¹¹

Smaller Carriers

Sutter Health Plan covers medications for morbid obesity (BMI of 40 or higher) and classifies Zepbound as a non-formulary Tier 4 drug, requiring six months of enrollment in its “Vida” program. Western Health Advantage does not include GLP-1 weight-loss drugs on its formulary but allows a non-formulary exceptions process for members with a BMI above 40. Prominence Health Plan and MediExcel exclude GLP-1 coverage for weight loss and limit access to patients with documented type 2 diabetes.⁹

What Carriers Typically Require

If your plan does offer a path to coverage, expect to clear most of the following hurdles.

Prior authorization. Every carrier that covers Zepbound requires it. Your prescriber submits documentation before the pharmacy can fill the prescription. Processing typically takes one to seven business days, though complex cases can stretch to several weeks.¹²
BMI threshold. The FDA approves Zepbound for BMIs as low as 27 with a comorbidity, but several Covered California carriers set the bar at a BMI of 40 or higher for marketplace enrollees.⁷
Weight-management program. Most plans require documentation of participation in a structured program combining diet, exercise, and behavioral modification, typically for at least six months before starting the drug and continuing through treatment.⁵
Step therapy. Some insurers require you to try and fail on lower-cost weight-loss medications first. Commonly required alternatives include phentermine, Contrave, Qsymia, and Wegovy.¹³
Reauthorization. Coverage is not open-ended. Plans typically reauthorize after six to twelve months and often require documentation showing at least a 5% reduction from baseline body weight.

The Sleep Apnea Pathway

Zepbound’s FDA approval for moderate-to-severe obstructive sleep apnea in adults with obesity opens a separate coverage route that can bypass weight-loss exclusions.² No other GLP-1 drug carries this indication, which gives patients with a qualifying sleep apnea diagnosis a strong basis for requesting a formulary exception even on plans that treat Zepbound strictly as a weight-loss drug.

To qualify under this pathway, you generally need a sleep study showing an apnea-hypopnea index of 15 or more events per hour, a BMI of at least 30, and clinical documentation tying the prescription to the sleep disorder rather than to weight loss alone.¹¹ Some plans also require evidence that you have tried or cannot use CPAP therapy. Coding the prescription under the ICD-10 code for obstructive sleep apnea rather than obesity is critical for getting the claim processed through this pathway.

Medi-Cal Rules Do Not Apply To Covered California

If you are reading news about California cutting Zepbound coverage, that story is about Medi-Cal, not Covered California. The two programs share an application but operate under different rules.¹⁴ Effective January 1, 2026, Medi-Cal stopped covering Zepbound, Wegovy, and Saxenda when prescribed for weight loss in adults 21 and older.¹⁵ That rule does not apply to Covered California marketplace plans, which continue to follow their own carrier-specific formularies. If your income changes and you move between the two programs, assume your coverage for Zepbound changes as well.

What Zepbound Costs Without Coverage

If your plan denies the drug or you cannot meet the authorization criteria, the out-of-pocket price is steep. Zepbound’s wholesale list price ranges from $499 to about $1,086 for a 28-day supply.¹⁶ Retail pharmacy prices for the single-dose pen average around $1,291 per month.¹⁷

Eli Lilly offers manufacturer savings programs that reduce the cost for most Covered California enrollees, since marketplace plans count as commercial insurance.

If your plan covers Zepbound, Lilly’s savings card can bring your cost down to as little as $25 per month, subject to an annual savings cap of $1,300.¹⁸
If your plan does not cover Zepbound, you can buy the KwikPen directly from Lilly starting at $299 per month for the 2.5 mg dose and $449 per month for higher doses. The single-dose pen is around $499.
If you are uninsured or paying entirely out of pocket, similar KwikPen pricing is available through Lilly’s Self Pay Journey Program, provided you refill within 45 days.¹⁹

All Lilly savings programs expire December 31, 2026. Patients on Medicare, Medicaid (including Medi-Cal), TRICARE, or VA benefits are not eligible for any of these discounts.¹⁸

If Your Claim Is Denied

Denials are common and often appealable. If your plan denied Zepbound under a weight-loss exclusion and you have a qualifying sleep apnea diagnosis, ask your prescriber to resubmit under the obstructive sleep apnea indication with a sleep study attached. If the denial cites lack of medical necessity, your prescriber can submit a letter of medical necessity with supporting clinical documentation; Lilly publishes a medical appeals guide and notes that multiple rounds of appeals are sometimes required.¹² Call the member services number on your insurance card to confirm the specific grounds for denial and your deadline to appeal, and check Covered California’s prescription guidance for your rights as an enrollee.⁴

One California bill to watch is Assembly Bill 575, which would require state-regulated health plans to cover at least one GLP-1 anti-obesity medication without prior authorization and prohibit coverage criteria more restrictive than the FDA label.²⁰ The bill has not been enacted, and its committee and vote status have not been publicly confirmed. For now, your coverage rides on your carrier’s current formulary, not on what may be coming.

1
FDA. Zepbound Prescribing Information
2
FDA. FDA Approves First Medication for Obstructive Sleep Apnea
3
MedicareResources.org. Will Your Health Insurance Cover Weight Loss Medications
4
Covered California. Prescriptions
5
Blue Shield of California. Weight Loss Medication Coverage Change Fact Sheet
6
Health Net. Weight Loss Medications Coverage Criteria
7
Health Net. Clinical Policy for Tirzepatide
8
Health Net. Weight Loss Drug Buy-Up Flyer
9
Word & Brown. Weight Loss Drugs (GLP-1) Coverage
10
Kaiser Permanente. Commercial HMO Formulary
11
UnitedHealthcare. Clinical Pharmacy Program for Zepbound
12
Eli Lilly. Zepbound Access and Coverage
13
FindHonestCare. Zepbound Prior Authorization
14
Covered California. Medi-Cal
15
Medi-Cal Rx. Important Update on GLP-1s for Weight Loss
16
Eli Lilly. Zepbound Pricing Information
17
GoodRx. Zepbound Cost
18
Eli Lilly. Zepbound Savings
19
Eli Lilly. Zepbound Coverage and Savings for HCPs
20
CHBRP. Key Findings for AB 575 Obesity Treatment